作者: Qiushi Wang , Yong He , Xin Yang , Yubo Wang , Hualiang Xiao
关键词:
摘要: Background The discovery of the fusion gene echinodermmicro tubule associated proteinlike 4-anaplastic lymphoma kinase, EML4-ALK, in patients with non-small-cell lung cancer has led to remarkable development anaplastic kinase inhibitors, such as crizotinib. Consequently, clinical outcomes these have improved dramatically. Herein, we report case a woman ALK translocation-squamous cell who experienced tumor response crizotinib after two courses failed chemotherapy.